Clinical studyRadiofrequency Ablation in the Management of Unresectable Intrahepatic Cholangiocarcinoma
Section snippets
Subjects
After institutional review board approval, a retrospective review of medical and imaging records of consecutive patients treated for ICC with RF ablation was performed. There were 30 patients with ICC who presented to our center for RF ablation treatment; 17 of these patients met our criteria. These 17 patients received RF ablation between January 2000 and July 2010. The remaining 13 patients were excluded for nodular ICCs > 7 cm in maximum diameter (6 patients), multifocal lesions (greater
Local Tumor Control
The early ablation success rate after the first RF ablation based on the CT findings at 1 month was 96.2% (25 of 26 tumors, 17 sessions). One patient with recurrent ICC who had residual tumor after initial RF ablation received a second RF ablation, and the tumor was ablated successfully by repeated treatment.
Recurrence Data
After a median follow-up period of 29 months, local recurrence after RF ablation developed in three patients (one patient with primary tumor, two patients with recurrent tumors). All three
Discussion
In recent years, RF ablation has been shown to be effective for treatment of ICC in selected patients (21, 22, 23, 24, 28, 29, 30, 31). For primary ICC, Carrafiello et al (30) reported the results for six patients who underwent percutaneous ultrasound-guided RF ablation. CT scan performed after treatment showed total necrosis in four of six (66%) tumors. However, in this study, no long-term survival data were available owing to a short follow-up period. Kim et al. (28, 31) reported the largest
References (39)
- et al.
Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma
Am J Surg
(2002) - et al.
Intrahepatic cholangiocarcinoma: resectability, recurrence, and outcomes
J Am Coll Surg
(2001) - et al.
Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma
Clin Radiol
(2011) - et al.
Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution
J Vasc Interv Radiol
(2005) - et al.
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer
Ann Oncol
(2001) - et al.
Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma
Kaohsiung J Med Sci
(2005) - et al.
Treatment strategy to optimize radiofrequency ablation for liver malignancies
J Vasc Interv Radiol
(2006) - et al.
Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
Dig Liver Dis
(2008) - et al.
Pathological aspects of cholangiocarcinoma
J Pathol
(1983) Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings
AJR Am J Roentgenol
(2003)
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
Ann Surg
Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma
World J Surg
What prognostic factors are important for resected intrahepatic cholangiocarcinoma?
J Gastroenterol Hepatol
Surgical treatment of cholangiocarcinoma
Hepatogastroenterology
Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study
Gut Liver
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy
J Cancer Res Clin Oncol
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study
Cancer
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
N Engl J Med
Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients
Cancer J
Cited by (72)
Long non-coding RNA HAGLROS regulates lipid metabolism reprogramming in intrahepatic cholangiocarcinoma via the mTOR signaling pathway
2020, Experimental and Molecular PathologyCitation Excerpt :In the early stage, radical tumor resection or liver transplantation is the only treatment, but most advanced ICC patients still have recurrence after operation (Hoffmann et al., 2012; Sia et al., 2013). Complete resection, which was feasible for 18%–70% ICC patients, resulted in about 30% of 5-year survival rate, and nearly 2–3 years of median overall survival (Fu et al., 2012). Because ICC usually has no obvious clinical symptoms in the early stage, the surgery is no longer feasible for most advanced patients possibly due to size, location or proliferation of the tumors (Hoffmann et al., 2012).
Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients
2020, Journal of Vascular and Interventional RadiologyS3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms - Langversion 4.0
2023, Zeitschrift fur Gastroenterologie
Funding provided by The National Science Foundation for Young Scholars of China (No. 81101745) and incubation fund of public health plan of BSTC (Beijing Science Technology Commission, Z111107067311026).
None of the authors have identified a conflict of interest.